You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
GaN Quad-Active-Bridge Converter for Hybrid PV-Battery Systems
SBC: EPOWER TECHNOLOGY LLC Topic: C5615aA quad-active-bridge (QAB) multiport converter will be developed based on an innovative circuit topology, a high-frequency planar magnetic transformer, and the latest generation of wide bandgap (WBG) transistors. The WBG-based QAB converter will provide a high-efficiency and ultra-compact interface capable of connecting with an array of photovoltaic (PV) panels, battery packs, electric vehicles (E ...
STTR Phase I 2023 Department of Energy -
Commercial Production of the Group-V Doped Polycrystalline CdTe Source Material for the Next-Generation Photovoltaics
SBC: RADIATION DETECTION TECHNOLOGIES, INC. Topic: C5416aCdTe photovoltaic (PV) module performance has room to improve and can help the DOE in achieving its SunShot initiative. Improving the p-type doping and carrier lifetime in polycrystalline CdTe absorber material is critical to achieving PV cell efficiency to 25%. The current industrial supply chain consists of CdTe feedstock that undergoes treatments to help improve the material properties in effor ...
STTR Phase II 2023 Department of Energy -
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
SBC: Metselex, Incorporated Topic: 105ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells
SBC: MARPAM PHARMA LLC Topic: NIAIDProject Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B
SBC: NECTAGEN INC Topic: NIAIDInfection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Two-for-one Stroke Thrombectomy:A novel Dual DAC to enhance navigability, lumen size, aspiration efficiency, and persistent flow arrest in mechanical thrombectomy
SBC: PIRAEUS MEDICAL, INC. Topic: 105PROJECT SUMMARY/ABSTRACT The long-term goal of this proposal is to improve the care of patients suffering from Large Vessel Occlusion Acute Ischemic stroke. Currently, mechanical thrombectomy techniques can achieve revascularization in over 70% of cases, and physicians are rapidly adoption aspiration thrombectomy over stent-trievers. Aspiration maintains equivalent angiographic and clinical outcom ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)
SBC: SMART INFORMATION FLOW TECHNOLOGIES LLC Topic: NHGRIPROJECT SUMMARY Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the U ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Prodrugs of potent and selective protease inhibitors as tauopathy therapeutics
SBC: MYRIEL, INC. Topic: 105PROJECT ABSTRACT Myriel, Inc., is a pharmaceutical start-up company founded in 2022 to find cures for tauopathies, including Alzheimer’s disease and related dementias (ADRD), which impair cognition in 32% of US adults 65 years and older. The goal of this Phase 1 STTR application is to provide Myriel with a brain-penetrant analogue of our lead compound, GPHR ‘739, the first potent, selective, r ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health